A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
Latest Information Update: 22 Apr 2024
At a glance
- Drugs CM 326 (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- Sponsors KeyMed Biosciences
Most Recent Events
- 22 Apr 2024 New trial record